+

WO2003039482A3 - Polymorphes a base fexofenadine - Google Patents

Polymorphes a base fexofenadine Download PDF

Info

Publication number
WO2003039482A3
WO2003039482A3 PCT/US2002/035996 US0235996W WO03039482A3 WO 2003039482 A3 WO2003039482 A3 WO 2003039482A3 US 0235996 W US0235996 W US 0235996W WO 03039482 A3 WO03039482 A3 WO 03039482A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphs
fexofenadine base
forms
present
fexofenadine
Prior art date
Application number
PCT/US2002/035996
Other languages
English (en)
Other versions
WO2003039482A2 (fr
WO2003039482A8 (fr
Inventor
Barnaba Krochmal
Dov Diller
Ben-Zion Dolitzky
Judith Aronhime
Shlomit Wizel
Original Assignee
Teva Pharma
Barnaba Krochmal
Dov Diller
Ben-Zion Dolitzky
Judith Aronhime
Shlomit Wizel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/118,807 external-priority patent/US20020177608A1/en
Priority claimed from US10/133,460 external-priority patent/US20030021849A1/en
Application filed by Teva Pharma, Barnaba Krochmal, Dov Diller, Ben-Zion Dolitzky, Judith Aronhime, Shlomit Wizel filed Critical Teva Pharma
Priority to EP02792238A priority Critical patent/EP1453509A2/fr
Priority to IL16181602A priority patent/IL161816A0/xx
Priority to JP2003541774A priority patent/JP2005537218A/ja
Priority to AU2002357701A priority patent/AU2002357701A1/en
Priority to CA002465913A priority patent/CA2465913A1/fr
Publication of WO2003039482A2 publication Critical patent/WO2003039482A2/fr
Publication of WO2003039482A3 publication Critical patent/WO2003039482A3/fr
Publication of WO2003039482A8 publication Critical patent/WO2003039482A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles formes cristallines à base fexofénadine et des procédés de préparation de celles-ci. Ces formes sont administrées à des êtres humains et à des animaux afin de soulager les symptômes entraînés par l'histamine. Cette invention concerne, en outre, des compositions pharmaceutiques de ces nouvelles formes cristallines.
PCT/US2002/035996 2001-11-08 2002-11-08 Polymorphes a base fexofenadine WO2003039482A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02792238A EP1453509A2 (fr) 2001-11-08 2002-11-08 Polymorphes a base fexofenadine
IL16181602A IL161816A0 (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base
JP2003541774A JP2005537218A (ja) 2001-11-08 2002-11-08 フェキソフェナジン塩基の多形体
AU2002357701A AU2002357701A1 (en) 2001-11-08 2002-11-08 Polymorphs of fexofenadine base
CA002465913A CA2465913A1 (fr) 2001-11-08 2002-11-08 Polymorphes a base fexofenadine

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US33693001P 2001-11-08 2001-11-08
US60/336,930 2001-11-08
US33904101P 2001-12-07 2001-12-07
US60/339,041 2001-12-07
US34411401P 2001-12-28 2001-12-28
US60/344,114 2001-12-28
US36178002P 2002-03-04 2002-03-04
US60/361,780 2002-03-04
US36348202P 2002-03-11 2002-03-11
US60/363,482 2002-03-11
US10/118,807 2002-04-08
US10/118,807 US20020177608A1 (en) 2001-04-09 2002-04-08 Polymorphs of fexofenadine hydrochloride
US10/133,460 2002-04-26
US10/133,460 US20030021849A1 (en) 2001-04-09 2002-04-26 Polymorphs of fexofenadine hydrochloride
US38767002P 2002-06-10 2002-06-10
US60/387,670 2002-06-10
US39019802P 2002-06-19 2002-06-19
US60/390,198 2002-06-19
US40376502P 2002-08-15 2002-08-15
US60/403,765 2002-08-15
US40621402P 2002-08-27 2002-08-27
US60/406,214 2002-08-27

Publications (3)

Publication Number Publication Date
WO2003039482A2 WO2003039482A2 (fr) 2003-05-15
WO2003039482A3 true WO2003039482A3 (fr) 2003-11-20
WO2003039482A8 WO2003039482A8 (fr) 2005-01-06

Family

ID=29424979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035996 WO2003039482A2 (fr) 2001-11-08 2002-11-08 Polymorphes a base fexofenadine

Country Status (4)

Country Link
EP (1) EP1453509A2 (fr)
AU (1) AU2002357701A1 (fr)
CA (1) CA2465913A1 (fr)
WO (1) WO2003039482A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
WO2006037042A1 (fr) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Forme de cristal de fexofenadine et ses processus de preparation
CN114890943A (zh) 2013-11-15 2022-08-12 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US5589487A (en) * 1993-06-24 1996-12-31 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6201124B1 (en) * 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US5589487A (en) * 1993-06-24 1996-12-31 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6201124B1 (en) * 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"X-ray diffraction", NATIONAL FORMULARY, 1995, pages 1843 - 1844, XP002963646 *

Also Published As

Publication number Publication date
WO2003039482A2 (fr) 2003-05-15
CA2465913A1 (fr) 2003-05-15
EP1453509A2 (fr) 2004-09-08
AU2002357701A1 (en) 2003-05-19
WO2003039482A8 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
EP1887007A3 (fr) Imidazo- et thiazolopyridines en tant qu'inhibiteurs de la JAK3 kinase
EP1416933B8 (fr) Piperidines substituees utilisees comme modulateurs du recepteur de la melanocortine
WO2003028641A3 (fr) Antagonistes du recepteur de la mch
CA2466724A1 (fr) Benzamide et heteroarylamide utilises comme antagonistes du recepteur p2x7
PL370381A1 (en) Substituted piperazines as modulators of the melanocortin receptor
WO2004007457A3 (fr) Derives de benzylamine substitues et procedes d'utilisation
IL159960A (en) Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
SE0101675D0 (sv) Novel composition
WO2002068406A3 (fr) Derives d'amines substituees et procede d'utilisation
WO2005033099A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
WO2006020959A3 (fr) Heterocycles benzo-condenses substitues
WO2005061467A3 (fr) Derives de piperazine et procedes pour les utiliser
WO2002080857A3 (fr) Polymorphes de chlorhydrate de fexofenadine
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
WO2005080345A3 (fr) Derives d'imidazoline a activite antagoniste cb1
WO2004050618A3 (fr) Forme cristalline
WO2005075467A3 (fr) Formes cristallines de zolmitriptan
WO2003039482A3 (fr) Polymorphes a base fexofenadine
WO2004026837A3 (fr) Antagonistes du recepteur h3 d'histamine, preparation et applications therapeutiques
WO2001081298A3 (fr) Acides carboxyliques cycliques comme antagonistes d'integrines
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques
WO2004037844A8 (fr) Gamma-lactone de l'acide carboxylique 17beta-hydroxy-7alpha-(5'-methyl-2'-furyl)-pregna-4,9(11)-diene-3-one-21
WO2002044128A3 (fr) Analogues de salicylate utilises en tant qu'antagonistes d'interleukine-4
WO2003004460A3 (fr) Derives d'acide succinique
WO2003005970A3 (fr) Polymorphe de carvedilol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2465913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 161816

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003541774

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002792238

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002792238

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002792238

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 20/2003 UNDER (30) REPLACE "60/387, 670, 06 OCTOBER 2002 (06.10.2002), US" BY "60/387, 670, 10 JUNE 2002 (10.06.2002), US"

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载